MedTrace Logo

Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

NCT05560555 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2024-05-13

Study results available
· View outcomes & findings →

Summary

A study of patients with hereditary transthyretin amyloidosis (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt) that have been enrolled in B3461028 and B3461045 studies in Spain - exposed to tafamidis 61mg for ≥12 months with polyneuropathy (PN) have kept going to their multisystemic follow-ups (neuro/ophthalmo/gastrointestinal) ≥12 months.

Conditions

  • Hereditary Transthyretin Amyloidosis (ATTRv)
  • Polyneuropathy

Interventions

DRUG

Tafamidis

61 milligrams (mg) as received in studies B3461028 and B3461045

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-24
Primary Completion
2022-11-15
Completion
2022-11-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05560555 on ClinicalTrials.gov